MACROGENICS Business Summary

MacroGenics Inc. (MGNX) is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative antibody-based therapeutics for cancer. The company generates revenue through a multi-faceted business model that includes strategic collaboration and milestone payments from global partners, contract development and manufacturing organization (CDMO) services, and the strategic monetization of assets, such as royalty purchase agreements. Its primary business segments are centered on its proprietary technology platforms, including DART (Dual-Affinity Re-Targeting) and TRIDENT (multi-specific), which enable the engineering of bispecific antibodies and antibody-drug conjugates (ADCs). MacroGenics competes directly with oncology-focused biotechs such as Mersana Therapeutics, NGM Biopharmaceuticals, Monopar Therapeutics, and Agios Pharmaceuticals. Within this landscape, MacroGenics distinguishes itself as a specialized platform-play that leverages high-value oncology assets like lorigerlimab and MGC026 to secure non-dilutive capital through partnerships with industry giants like Incyte, Gilead Sciences, and Sanofi. MacroGenics was founded in 2000 by a distinguished scientific team including Dr. Scott Koenig, Dr. Jeffrey Ravetch, Dr. LeRoy Hood, Dr. Ruedi Aebersold, and Dr. Alan Aderem. The current leadership team is headed by President and CEO Eric Risser, who assumed the role in August 2025 after serving as the company’s COO and leading corporate development efforts that generated over $1.6 billion in capital. The executive suite includes Dr. Ezio Bonvini as Senior VP and Chief Scientific Officer, who brings extensive regulatory experience from the FDA, and James Karrels as Senior VP and CFO, formerly of Jazz Pharmaceuticals. The company’s Board of Directors is chaired by William Heiden and includes former CEO Dr. Scott Koenig as an advisor. MacroGenics maintains a strong institutional investor base, with notable backing from firms such as Bellevue Group AG, Ridgeback Capital Management, and Tekla Capital Management.